Kineta Board Member's Complex Stock Moves Signal Confidence Despite Sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kineta Director Raymond J. Bartoszek reported multiple stock transactions on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share
- Disposed of 4,706 shares at $0.26 per share through tax withholding (F)
- Received 6,000 new shares as a grant on June 25
Following these transactions, Bartoszek directly owns 31,000 shares and indirectly controls 1,750,474 additional shares through: RLB Holdings Connecticut LLC (1,748,473 shares), his son (1,001 shares), and daughter (1,000 shares). The stock option exercise was triggered by an Optionholder Treatment Agreement dated June 16, 2025, related to a merger agreement between Kineta and TuHURA Biosciences. The options, granted under the 2022 Equity Incentive Plan, became fully vested on June 23, 2025.
Positive
- Director received 6,000 shares as compensation grant, demonstrating continued alignment with shareholder interests
- Director maintains significant indirect ownership of 1.75M shares through RLB Holdings Connecticut LLC, showing substantial long-term commitment to the company
Negative
- None.
Insider Trade Summary
12,500 shares exercised/converted
Mixed
7 txns
Insider
Bartoszek Raymond J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 6,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Exercise | Common Stock | 12,500 | $0.611 | $8K |
| Tax Withholding | Common Stock | 4,706 | $0.26 | $1K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 31,000 shares (Direct);
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 1,748,473 shares (Indirect, By RLB Holdings Connecticut, LLC)
Footnotes (1)
- The Reporting Person is a managing member of RLB Holdings Connecticut, LLC ("RLB") and shares voting and dispositive power over the shares held by RLB. As such, the Reporting Person may be deemed to beneficially own such shares held by RLB. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.
FAQ
What insider transactions did Raymond Bartoszek make in KA stock on June 23, 2025?
On June 23, 2025, Raymond Bartoszek exercised 12,500 stock options at $0.611 per share (acquired) and then disposed of 4,706 shares at $0.26 per share through a tax withholding transaction (F code). Additionally, on June 25, 2025, he acquired 6,000 shares at $0.
What was the exercise price of KA stock options that Bartoszek exercised?
Raymond Bartoszek exercised stock options with a conversion price of $0.611 per share. These options were originally set to expire on September 3, 2034, but became fully vested on June 23, 2025, due to the TuHURA Biosciences merger agreement.
What triggered the vesting of Bartoszek's KA stock options in June 2025?
The stock options vested due to the Optionholder Treatment Agreement dated June 16, 2025, and the Agreement and Plan of Merger with TuHURA Biosciences, which was approved by stockholders at the Special Meeting on June 23, 2025. This agreement triggered full vesting of options granted under the 2022 Equity Incentive Plan.